Abstract
The Omission of Axillary Lymph Node Dissection in Sentinel Node-Positive Breast Cancer Patients Requires Careful Consideration
Highlights
Sentinel Lymph Node Biopsy (SNB) is coming to replace axillary lymph node dissection as a method of accurately assessing axillary nodes in clinically lymphatic metastasis-negative breast cancer patients [1,2,3]
The rate of non-SN metastasis positivity was significantly higher in patients who had tumors over expressing Human Epidermal Growth Factor Receptor-2 (HER2) (P = 0.035)
When we compared whether the number of removed SNs was larger than or equal to the number of metastatic SNs, we found that the frequency of non-SN metastasis was significantly lower in the group for which the number of removed SNs was higher than the number of metastatic SNs, as shown in Table 4 (P = 0.003)
Summary
Sentinel Lymph Node Biopsy (SNB) is coming to replace axillary lymph node dissection as a method of accurately assessing axillary nodes in clinically lymphatic metastasis-negative breast cancer patients [1,2,3]. The omission of axillary lymph node dissection is recommended if a patient is Sentinel Lymph Node (SN) metastasis-negative. Several recent prospective randomized comparative studies have showed an improved prognosis after omitting axillary node dissection, even in the presence of micrometastases or two or fewer macrometastases in the SN [4,5,6,7]. The purpose of the present study was to retrospectively examine the association among non-SN metastasis status, clinicopathological factors, the number of metastatic SNs, and the number of removed SNs in patients with one or two metastatic SNs from the prospective SNB database in our department
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
